(GNHAY) – Business Wire
-
Cancellation of remaining publicly held registered shares of Vifor Pharma AG
-
Ferinject® approved in Chinafor the treatment of iron deficiency in adult patients
-
Approval of extension of exemptions from SIX disclosure and publicity obligations
-
Approval of delisting of Vifor Pharma AG's registered shares
-
CSL Vifor and Travere Therapeutics announce EMA has accepted for review the Conditional Marketing Authorization application for sparsentan for the treatment of IgA Nephropathy
-
VFMCRP announces U.S. Court upholds validity of Velphoro® patent
-
Kapruvia® approved in Switzerland with additional regulatory decisions expected in H2 2022
-
Tavneos® (avacopan) recommended by England’s NICE for the treatment of AAV (GPA/MPA)
-
Finalization of Vifor Pharma acquisition
-
Extension of the postponement of the settlement of Vifor Pharma tender offer
-
Update on the timeline for Vifor Pharma tender offer
-
Kapruvia® approved by European Commission for the treatment of moderate-to-severe pruritus in hemodialysis patients
-
94th Vifor Pharma Group Annual General Meeting
-
DIAMOND trial: Veltassa® enables patients to achieve long-term potassium control and optimized RAASi therapy
-
Publication of definitive end result for Vifor Pharma tender offer
-
Publication of provisional end result for Vifor Pharma tender offer: Participation rate of 94 percent
-
Publication of definitive Interim Result for Vifor Pharma tender offer: CSL Behring AG declares offer successful
-
Publication of provisional interim result for Vifor Pharma tender offer: Participation rate of 74 percent
-
Kapruvia® receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodialysis patients
-
Vifor Pharma reports sustained growth in 2021
-
Vifor Pharma appoints two new members to the Executive Committee
-
VFMCRP receives EU approval for Tavneos® for the treatment of ANCA-associated vasculitis
-
CSL Behring AG publishes Offer Prospectus on public tender offer for all publicly held shares of Vifor Pharma Ltd.
-
Vifor Pharma reports positive outcome of the phase-IIIb DIAMOND trial of Veltassa®
-
Vifor Pharma and American Regent announce settlement of Injectafer® patent litigation
-
Vifor Pharma drives transformation with divestment of non-core finished drug manufacturing to CordenPharma
-
CSL Limited announces tender offer to acquire Vifor Pharma Ltd
-
Vifor Pharma comments on media speculation
-
First patient enrolled in phase-IIa study of vamifeport in patients with sickle cell disease
-
Vifor Pharma appoints Hervé Gisserot as new Chief Commercial Officer and member of the Executive Committee
-
Vifor Pharma and Angion report topline results from phase-II GUARD trial of ANG-3777 in cardiac surgery associated acute kidney injury
-
Vifor Pharma comments on market speculations
-
Vifor Pharma announces changes to the Executive Committee as CFO retires
-
Vifor Pharma supports Iron Deficiency Day 2021: Call to action for early iron deficiency diagnosis
-
Vifor Pharma to spearhead development of vascular calcification field, through acquisition of Sanifit Therapeutics and Inositec AG
-
VFMCRP receives positive CHMP opinion for Tavneos® for the treatment of ANCA-associated vasculitis
-
Vifor Pharma and Angion report topline results from phase-III registration trial of ANG-3777 in kidney transplant patients at risk for delayed graft function
-
Vifor Pharma announces changes to its Executive Committee
-
VFMCRP announces approval for TAVNEOS® (avacopan) for the treatment of ANCA-associated vasculitis in Japan
-
Vifor Pharma and Travere Therapeutics announce licensing agreement for the commercialization of sparsentan in Europe, Australia and New Zealand
-
Vifor Pharma’s Ferinject® granted new recommendations in updated 2021 ESC heart failure guidelines
-
Vifor Pharma and Cara Therapeutics announce U.S. FDA approval of KORSUVA™ injection for the treatment of moderate-to-severe pruritus in hemodialysis patients
-
Vifor Pharma reports strong H1 2021 growth, on track to meet full year guidance¹
-
Abbas Hussain Appointed as New Chief Executive Officer of Vifor Pharma
-
Vifor Pharma to revise DIAMOND study, readout expected in H2 2021
-
93rd Vifor Pharma Group Annual General Meeting
-
VFMCRP announces positive results of phase-III clinical trial of Velphoro® in China
-
Vifor Pharma and Angion announce completion of enrollment in phase-II study of ANG-3777 for cardiac-surgery associated acute kidney injury
-
First patient enrolled in CARE-HK in HF to evaluate role of Veltassa® (patiromer) in enabling RAASi treatment
-
VFMCRP and Cara Therapeutics announce European Medicines Agency has accepted to review the Marketing Authorization Application for difelikefalin
Back to GNHAY Stock Lookup
